Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

23 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Nplate Articles

More news briefs from ASH meeting

14 December 2011

FDA eases REMS requirements for Amgen’s Nplate and GSK’s Promacta

7 December 2011

UK NICE gives final yes for Amgen’s Nplate but no for PharmaMar’s Yondelis

27 April 2011

Amgen buys Bergamo for $215 million, thus establishing commercial operations in Brazil

11 April 2011

2010 Prix Galien winners include Merck & Co, Novartis, Amgen and Bayer

6 April 2011

UK’s NICE backs Merck & Co’s Simponi and Amgen’s Nplate

18 March 2011

UK’s NICE recommends Amgen’s Nplate for idiopathic thrombocytopenic purpura

2 December 2010

Novartis, Amgen, GSK and Veridex among Prix Galien USA Honors recipients

2 October 2009

Amgen's Nplate reduces number of splenectomies

8 June 2009

Amgen gets EC appro for Nplate in ITC

16 February 2009

FDA 2008 NCE appros exceed expectations

12 January 2009

ASH hears strong data on Novartis

22 December 2008

74% of ITP patients achieve platelet response on Nplate

15 December 2008

CHMP gives nod to four new drugs at meeting

1 December 2008

FDA approves Amgen

1 September 2008

Expected US approval of Amgen

28 July 2008

Long-term use potential for romiplostim

23 June 2008

FDA expert panel recommends Amgen ITP drug

17 March 2008

Amgen's romiplostim meets Phase III endpoints in ITP

17 December 2007

Amgen files romiplostim NDA with US FDA

29 October 2007

Showing 1-20 of 20 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS